GlassScriptPhysician profile
Scot C Holman
NPI 1467533505
$20,022.93
in general payments reported to CMS, 2019-2025
24 companies · $2,405 in 2025
The $2,405 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $171 · 2021: $546 · 2022: $1,097 · 2023: $946 · 2024: $968 · 2025: $2,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,846 · Entertainment: $1,297 · Long Term Medical Supply Or Device Loan: $150 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,845.93 |
| Entertainment | $1,297.20 |
| Long Term Medical Supply Or Device Loan | $150.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $14,550.27 | 2019-2024 | Catalys System, Tecnis Iol, Veritas Vision System |
| Nova Eye, INC. | $1,435.81 | 2024-2025 | |
| Ocular Therapeutix, INC. | $799.23 | 2023-2025 | Dextenza |
| Sight Sciences, INC. | $759.36 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $537.92 | 2020-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Abbvie INC. | $419.00 | 2022-2025 | |
| Allergan, INC. | $318.41 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $235.87 | 2019-2023 | |
| Rxsight INC | $219.90 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Biotissue Holdings INC. | $121.46 | 2021-2024 | |
| Rayner Intraocular Lenses Limited | $101.91 | 2024-2025 | Omidria, Rayone Aspheric, Rayone Spheric |
| Glaukos Corporation | $89.58 | 2025 | Idosetr, Istent Infinite |
| Ivantis, INC | $84.17 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $65.09 | 2019-2021 | |
| New World Medical,INC. | $53.84 | 2024-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $39.35 | 2025 | Xiidra |
| Oyster Point Pharma, INC. | $35.41 | 2022 | |
| Omeros Corporation | $34.08 | 2019-2021 | |
| Shire North American Group INC | $33.93 | 2019 | |
| Dompe US, INC. | $21.10 | 2025 | Oxervate |
| Beaver-Visitec International, INC. | $20.87 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.58 | 2021 | |
| Mallinckrodt Hospital Products INC. | $15.91 | 2025 | Acthar |
| Eyepoint US, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scot Holman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.